论文部分内容阅读
目的分析DEC1在胰腺癌组织中的表达及其与临床病理因素间的关系。方法采用免疫组化方法检测DEC1以及HIF-1α在68例胰腺管状腺癌中的表达情况。结果胰腺管状腺癌中DEC1的表达明显高于正常胰腺组织中DEC1的表达。在68例胰腺管状腺癌中,DEC1的阳性表达与胰腺管状腺癌的淋巴结转移(P=0.016)、TNM分期(P=0.006)以及HIF-1α(P=0.046)的表达呈负相关。另外,DEC1在高TNM分期的胰腺管状腺癌中出现表达缺失并与不良预后相关(P<0.001)。结论胰腺管状腺癌中DEC1的表达缺失与淋巴结转移和肿瘤的TNM分期及不良预后相关。
Objective To analyze the expression of DEC1 in pancreatic cancer and its relationship with clinicopathological factors. Methods Immunohistochemical method was used to detect the expression of DEC1 and HIF-1α in 68 cases of pancreatic adenocarcinoma. Results The expression of DEC1 in pancreatic ductal adenocarcinoma was significantly higher than that in normal pancreatic tissue. In 68 cases of pancreatic adenocarcinoma, the positive expression of DEC1 was negatively correlated with the lymph node metastasis (P = 0.016), TNM stage (P = 0.006) and HIF-1α (P = 0.046) in pancreatic adenocarcinoma. In addition, DEC1 showed loss of expression in pancreatic tubular adenocarcinomas with high TNM staging and was associated with poor prognosis (P <0.001). Conclusions The loss of DEC1 expression in pancreatic ductal adenocarcinoma is associated with lymph node metastasis and tumor TNM stage and poor prognosis.